French Biopharma Invests In Medidata Solutions, Inc. Technology To Drive Cutting-Edge Cancer And Rare Disease Research
Published: Nov 14, 2016
NEW YORK--(BUSINESS WIRE)--Medidata (NASDAQ: MDSO), the leading global provider of cloud-based solutions for clinical research in life sciences, today announced that Erytech Pharma (“Erytech”), a French biopharmaceutical company developing “tumor starvation” treatments for acute leukemia and other rare oncology indications, has adopted the Medidata Clinical Cloud® platform. Erytech will incorporate Medidata’s unified solution for randomization and electronic data capture (EDC) into its Phase I-III clinical trials. By leveraging Medidata’s cloud technology, Erytech seeks to simplify operational complexity and maximize scientific insights from its clinical data.
“Since Erytech’s inception, our mission has been to challenge aggressive diseases and improve patients’ lives by investing in the development of innovative, life-changing therapies”
The partnership represents an evolution in Erytech’s clinical operations strategy, as the company advances its pipeline of novel oncology and rare disease candidates for patients with unmet medical needs.
“Since Erytech’s inception, our mission has been to challenge aggressive diseases and improve patients’ lives by investing in the development of innovative, life-changing therapies,” said Iman El-Hariry, chief medical officer of Erytech. “Rare blood cancers and other orphan illnesses require some of the most intricate R&D work, which is why we’ve turned to a strong technology partner like Medidata to provide us with the scalable and configurable tools needed to overcome the complexities of these studies.”
Denise Tilton, Erytech’s head of clinical operations, added: “For many patients combating these serious and life-threatening conditions, time is of the essence. Medidata’s unified technology platform allows us to access clinical data in a timely fashion—increasing the speed and quality of our R&D programs, and empowering our researchers to continue pushing the frontiers of rare disease drug development.”
Founded in Lyon, France in 2004, Erytech is dedicated to developing therapies for patients with unmet medical needs. With a primary focus on rare blood cancers—including acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML)—and orphan diseases, Erytech is a leader in the ongoing development of two treatment methodologies: tumor starvation and drug substance encapsulation in red blood cells. To optimally support its development pipeline through improved clinical data quality and efficient randomization and treatment dispension, Erytech is implementing Medidata’s unified solution for EDC, management and reporting (Medidata Rave®) and trial randomization (Medidata Balance®) across its clinical research programs.
“We’re thrilled to be working with such a forward-thinking organization as Erytech,” said Christian Hebenstreit, Medidata’s managing director of the EMEA region. “With our scalable and configurable cloud technology platform, Erytech has the ability to conduct more informed clinical trials, enabling its researchers to significantly advance treatment options for patients across Europe and around the world. We look forward to supporting Erytech’s R&D efforts as they continue to tackle some of today’s most difficult-to-treat diseases.”
Connect with Medidata
- Read our blog, Geeks Talk Clinical
- Tweet this: .@Medidata & French #biopharma @ERYTECH_PHARMA collaborate to drive cutting-edge research for #cancer & #RareDisease http://ow.ly/ONQp3067Ahl
- Follow us on Twitter: @Medidata
- Find us on LinkedIn
Medidata is reinventing global drug development by creating the industry's leading cloud-based solutions for clinical research. Through our advanced applications and intelligent data analytics, Medidata helps advance the scientific goals of life sciences customers worldwide, including nearly 800 global pharmaceutical companies, innovative biotech, diagnostic and device firms, leading academic medical centers, and contract research organizations.
The Medidata Clinical Cloud® brings a new level of quality and efficiency to clinical trials that empower our customers to make more informed decisions earlier and faster. Our unparalleled clinical trial data assets provide deep insights that pave the way for future growth. The Medidata Clinical Cloud is the primary technology solution powering clinical trials for 17 of the world's top 25 global pharmaceutical companies, from study design and planning through execution, management and reporting.